Key
Management
We are a pharmaceutical development
company with experienced executives
and a shared vision to improve the
standard of cancer care.
Torsten Goesch, M.D., PhD, MBA
Co-founder, Non-Executive Director
Director of Rosetta Capital, London.
Former positions include General Manager,
Biogen & Commercial Head, Merck Generics.
Ningfeng Fiona Li, MD, PhD, MSc
Co-founder, Chief Executive Officer
Specialist in Clinical Oncology, with extensive research experience in tumour biology and carcinogenesis with publications in high impact journals.
Founder of London Nanjing Life Science (China) Ltd and Suzhou NG Biomedicine Ltd and developed several biotech reagent products, disinfectant products and small molecule pharmaceutical products through prototyping, clinical trials and recently marketing.
Paul Stainer, FCMA
Non-Executive Director, Finance Controller
Creative and experienced CFO & business
leader with a reputation for being a true
business partner to CEOs and leadership teams. This has been achieved in both regional and global roles working for US and Japanese Pharma, Medical Device companies.
Roger Widdowson, FCA
Non-Executive Director
Qualified Chartered Accountant. A commercial, collaborative and pragmatic Deal Advisory professional, a Partner retired from KPMG, over 20 years leadership on KPMG’s Global Healthcare and UK’s Private Sector Healthcare practice across all service lines, and the mid-market Life Sciences practice, responsible for business strategy and growth.
Torsten Goesch, M.D., PhD, MBA
Co-founder, Non-Executive Director
Director of Rosetta Capital, London. Former positions include General Manager, Biogen & Commercial Head, Merck Generics.
Ningfeng Fiona Li, MD, PhD, MSc
Co-founder, Chief Executive Officer
Specialist in Clinical Oncology, with extensive research experience in tumour biology and carcinogenesis with publications in high impact journals.
Founder of London Nanjing Life Science (China) Ltd and Suzhou NG Biomedicine Ltd and developed several biotech reagent products, disinfectant products and small molecule pharmaceutical products through prototyping, clinical trials and recently marketing.
Paul Stainer, FCMA
Non-Executive Director, Finance Controller
Creative and experienced CFO & business leader with a reputation for being a true business partner to CEOs and leadership teams. This has been achieved in both regional and global roles working for US and Japanese Pharma, Medical Device companies.
Roger Widdowson, FCA
Non-Executive Director
Qualified Chartered Accountant. A commercial, collaborative and pragmatic Deal Advisory professional, a Partner retired from KPMG, over 20 years leadership on KPMG’s Global Healthcare and UK’s Private Sector Healthcare practice across all service lines, and the mid-market Life Sciences practice, responsible for business strategy and growth.